NYSE
$0.6580▲ 2.80%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $12.7MShares out 19.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 9.25After-hours26.09.26 06:158-KKey event#●●●#●●●
Calidi Biotherapeutics, Inc.Bullish
Calidi Biotherapeutics has received a notice of non-compliance from NYSE American as its stockholders' equity of $3.1 million as of June 30, 2026, fell below the required $4.0 million threshold. The company must submit a compliance plan by October 21, 2026, and is required to regain compliance with listing standards by March 21, 2028.…more
$0.6580+2.80%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22After-hours26.09.23 06:008-KKey event
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics has raised approximately $1.2 million through a registered direct offering of 1,025,640 shares of common stock at a price of $1.17 per share. The offering closed on September 21, 2026, and the company intends to use the net proceeds for working capital and general corporate purposes.…more
$0.6580+2.80%vs prev closeView filingShare - 9.17After-hours26.09.18 06:00424B5Offering
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics has finalized a direct offering of 1,025,640 shares of common stock at $1.17 per share, raising gross proceeds of $1.2 million from accredited investors. The offering is conducted without an underwriter, and the proceeds will be available for immediate use by the company.…more
$0.6580+2.80%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:00#●●●#●●●
Calidi Biotherapeutics to Present Preclinical Data at ESMO 2026
Calidi Biotherapeutics will showcase new preclinical data for its oncology platforms at the upcoming ESMO Congress. As these are early-stage findings, the company's future stock performance will depend on successful clinical progression and the securing of strategic partnerships.…more
$0.6580+2.80%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.25After-hours26.09.26 06:00
●●●●●●●● ●●●●● ●●●●●●
Calidi Biotherapeutics has been notified by the NYSE American that it fails to meet the minimum stockholders' equity requirement for continued listing. The company must submit a compliance plan by October 2026 to avoid potential delisting proceedings.…more
$0.6580+2.80%vs prev close - 9.17Pre-market26.09.17 22:10
●●●●●●●● ●●●●● ●●●●●●
Calidi Biotherapeutics has announced a registered direct offering to raise approximately $1.2 million. The company intends to use the net proceeds for working capital and general corporate purposes.…more
$0.6580+2.80%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report